Pep-1 wasused to penetrate the BTB and home NPs to GBM cells through IL-13Rα2,while the CREKA peptide was designed to target fibrin-fibronectincomplexes, aiming to improve its retention in GBM. This evidence concerns the gene IL13RA2 and glioblastoma.